# Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer

> **NCT03888612** · PHASE1,PHASE2 · COMPLETED · sponsor: **Arvinas Inc.** · enrollment: 248 (actual)

## Conditions studied

- Prostate Cancer Metastatic

## Interventions

- **DRUG:** ARV-110

## Key facts

- **NCT ID:** NCT03888612
- **Lead sponsor:** Arvinas Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-01
- **Primary completion:** 2024-04-29
- **Final completion:** 2025-01-27
- **Target enrollment:** 248 (ACTUAL)
- **Last updated:** 2025-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03888612

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03888612, "Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT03888612. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*